Cynvenio Announces New Deployment of LiquidBiopsy® System at Leading Cancer Research Center in South Korea

This new application will allow us to deliver high-quality clinical test results faster from whole blood samples, taking our cancer patient care to the next level by personalizing their treatment.

Cynvenio Biosystems, Inc. a leader in liquid biopsy technology for cancer research and precision medicine, today announced that its LiquidBiopsy rare cell and cell-free isolation platform has been deployed at Severance Hospital of the Yonsei University Health System. Located in Gangnam-Gu, Seoul, Severance Hospital is one of the oldest and largest university hospitals in South Korea and has been treating patients continuously for 130 years.

The LiquidBiopsy system at Severance Hospital will enable quick-turnaround blood sample-to-sequence workflows supporting genomic research and testing for cancer patients. The system will support programs across various indications including breast, prostate and lung cancer.

“The LiquidBiopsy system will significantly improve our sequencing workflows, allowing our lab to operate at a higher scale,” said Joon Jeong, M.D., Ph.D., Professor of the Department of Surgery and Director of the Breast Cancer Center at Gangnam Severance Hospital. “This new application will allow us to deliver high-quality clinical test results faster from whole blood samples, taking our cancer patient care to the next level by personalizing their treatment.”

The LiquidBiopsy platform is a turn-key system that supports a number of key liquid biopsy applications, including the isolation of circulating tumor cells (CTCs) to gain access to their DNA and RNA, cell-free DNA (cfDNA), exosomes, and platelets. The platform delivers ultra-high purity output that enables downstream molecular characterization such as protein analysis of CTCs and…

Article Source…

Leave a Reply

Your email address will not be published. Required fields are marked *